Panacea Biotec is a leading research based Health Management Company, with an annual turnover of approx. Rs. 830 Crores. We are engaged in research, development, manufacture & marketing of Vaccines, Bio-Pharmaceuticals and Pharmaceuticals (Rx & OTC) of international quality and Health Services. All Panacea Biotec plants are accredited by international agencies and they follow current Good Manufacturing Practices, as per WHO guidelines.

Post : Medical Representative

Troikaa Pharma is a leading company with the remarkable ability to constantly innovate through creative Imagination. Our NDDS brands Dynapar AQ and Dynapar QPS are path breaking & have revolutionised pain care. The company is driven by a visionary leadership and a strong multicultural workforce representing more than 85 countries. It's state-of-the-art manufacturing facilities located at Thol, Dehradun and Sanand are accredited by global authorities including WHO, PIC/S, ANVISA Brazil, INVIMA & several other regulatory authorities.

At BaseSolve, we are transforming Genomics Data Science Technologies. We provide smart solutions for efficient analysis and management of Next Generation Sequencing data facilitating accurate insights for clinical diagnostics as well as scientific research.

Post : Sr Bioinformatics Scientist (2 positions)

FDA halts clinical trials of Deuruxolitinib due to the potential for thrombotic events seen in subjects. FDA has placed the IND on partial clinical hold and are requiring that subjects currently on studies to discontinue the dose.

It has been noted by the FDA that pulmonary embolism (Serious Adverse Events) occurring at the 12 mg BID dose in one of the long-term Open Label Extension (OLE) studies of Deuruxolitinib.

Astellas Pharma Inc and Pfizer Inc announced that XTANDI® (enzalutamide) plus leuprolide significantly reduced the risk of metastasis or death by 58% versus placebo plus leuprolide (Hazard Ratio [HR]: 0.42; 95% Confidence Interval [CI], 0.30–0.61; P<0.0001), as assessed by the primary endpoint of metastasis-free survival (MFS), in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as non-metastatic castration-sensitive prostate cancer or nmCSPC) with high-risk biochemical recurrence (BCR).

What the human genome is lacking compared with the genomes of other primates might have been as crucial to the development of humankind as what has been added during our evolutionary history, according to a new study led by researchers at Yale and the Broad Institute of MIT and Harvard.

India is one of the top-ranking countries in the field of basic research. Indian Science has come to be regarded as one of the most powerful instruments of growth and development, especially in the emerging scenario and competitive economy. In the wake of the recent developments and the new demands that are being placed on the S&T system, it is necessary for us to embark on some major science projects which have relevance to national needs and which will also be relevant for tomorrow's technology.

The BITS BioCyTiH Foundation (henceforth The Foundation) is a Section 8 non-profit company hosted by BITS Pilani under the National Mission of Interdisciplinary Cyber-Physical Systems (NM-ICPS) of Government of India (GOI). The mandate of the company is to fashion a platform that would foster translational research, innovation, skill development and training in areas of bio-cyber-physical systems (Bio-CPS) related to healthcare, agriculture, water and environment. The aim is to build state of the art national facilities across three campuses of BITS Pilani (viz.

Department of Health & Family Welfare, G.T.A, Darjeeling invites ONLINE application for different contractual posts under various health programmes from the eligible candidates as per criteria mentioned with attached notification against the sanctioned posts for Darjeeling, G.T.A. Online application will be accepted only through the wbhealth.gov. in/on line recruitment) under E-Governance "Online Recruitment" between midnight of 24thApril,2023 to midnight of 18th May,2023.

Walk In Interview is going to be held on 04.05.2023 to fill the following vacancies in Government Medical College Hospital, Deputy Director Health Services Office, Government Hospitals and Government Primary Health Centers under National Health Scheme in Tirupur District through District Health Society. Hence, eligible candidates are requested to attend this interview.

Post : Pharmacist - 01 Post

National Institute for Research in Reproductive Health formerly known as Institute for Research in Reproduction is a premier research institute of the Indian Council of Medical Research (ICMR). It is situated in the vicinity of a number of hospitals and research institutes in central Mumbai. Since its inception in 1970, it has been making vigorous efforts to improve the reproductive health of people through research, education and health care services.

The BITS BioCyTiH Foundation is a Section 8 non-profit company hosted by BITS Pilani under the National Mission of Interdisciplinary Cyber-Physical Systems (NM-ICPS) of Government of India (GOI). The mandate of the company is to fashion a platform that would foster translational research, innovation, skill development and training in areas of bio-cyber-physical systems (Bio-CPS) related to healthcare, agriculture, water and environment. The aim is to build state of the art national facilities across three campuses of BITS Pilani (viz.

Pulse is a fast-growing Pharmaceutical company with a vertically and diagonally integrated business model, focused on providing innovative product solutions to a large number of people around the world, to help them manage their health better & lead a quality life.

Post : Executive - Medical Affairs

Macleods Pharmaceuticals, fastest growing company was established in 1986. Ranked amongst the top 10 pharma companies with a strength of 20000 employees, operating in 140 plus countries. Our bioequivalence centre was established in 2005 and is responsible for conducting studies for filing product registrations with various regulatory authorities.

Clinical Trial

Panacea Biotec is a leading research based Health Management Company, with an annual turnover of approx. Rs. 830 Crores. We are engaged in research, development, manufacture & marketing of Vaccines, Bio-Pharmaceuticals and Pharmaceuticals (Rx & OTC) of international quality and Health Services. All Panacea Biotec plants are accredited by international agencies and they follow current Good Manufacturing Practices, as per WHO guidelines.

Jodas is a Global, specialty, innovation driven, emerging, generic bio- pharmaceutical company, that is asserting itself among the worlds foremost pharmaceutical companies. JEPL is having EU GMP certification of Oncology (orals), Contrast Media (SVP and LVP) and facility for Cephalosporins currently delivering the products like Anti-Cancer and Antibiotics.Jodas is a Global, specialty, innovation driven, emerging, generic bio- pharmaceutical company, that is asserting itself among the worlds foremost pharmaceutical companies.

Rusan Pharma Ltd. is a fully integrated global pharmaceutical company specializing in the treatment of Addiction and Pain Management.  We offer a complete range of products for de-addiction and pain management in countries across the globe including Europe, UK, Russia, CIS, South Africa, Mauritius, Nepal and Myanmar.

Action
FDA approved Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene (SOD1-ALS). Qalsody is an antisense oligonucleotide that targets SOD1 mRNA to reduce the synthesis of SOD1 protein. The approval was based on a reduction in plasma neurofilament light (NfL), a blood-based biomarker of axonal (nerve) injury and neurodegeneration. 

For the over 8 million people around the globe living with Type 1 diabetes, getting a host immune system to tolerate the presence of implanted insulin-secreting cells could be life-changing.

Rice University bioengineer Omid Veiseh and collaborators identified new biomaterial formulations that could help turn the page on Type 1 diabetes treatment, opening the door to a more sustainable, long-term, self-regulating way to handle the disease.